Results from an ongoing Phase 2 basket study, SUMMIT, evaluating the combination of Puma Biotechnology's (PBYI -4.7%) NERLYNX (neratinib) and AstraZeneca's (AZN -2.9%) FASLODEX (fulvestrant) in patients with HER2- or HER3-positive solid tumors showed a treatment benefit. The data were presented at the San Antonio Breast Cancer Symposium.
In the group of patients with HR+/HER2+ breast cancer who received the combination, the confirmed overall response rate was 30% (n=14/47), including four complete responders. The disease control rate (responders + stable disease) was 47% (n=22/47). Median duration of response was 9.2 months.
Subscribe for full text news in your inbox